Details

Autor(en) / Beteiligte

• Jones, Melanie A.
• Rhodenizer, Devin
• da Silva, Cristina
• Huff, Israel J.
• Keong, Lisa
• Bean, Lora J.H.
• Coffee, Bradford
• Collins, Christin
• Tanner, Alice K.
• He, Miao
• Hegde, Madhuri R.

Titel

Molecular diagnostic testing for congenital disorders of glycosylation (CDG): Detection rate for single gene testing and next generation sequencing panel testing

Ist Teil von

• Molecular genetics and metabolism, 2013-09, Vol.110 (1-2), p.78-85

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Congenital disorders of glycosylation (CDG) are comprised of over 60 disorders with the majority of defects residing within the N-glycosylation pathway. Approximately 20% of patients do not survive beyond five years of age due to widespread organ dysfunction. A diagnosis of CDG is based on abnormal glycosylation of transferrin but this method cannot identify the specific gene defect. For many individuals diagnosed with CDG the gene defect remains unknown. To improve the molecular diagnosis of CDG we developed molecular testing for 25 CDG genes including single gene testing and next generation sequencing (NGS) panel testing. From March 2010 through November 2012, a total of 94 samples were referred for single gene testing and 68 samples were referred for NGS panel testing. Disease causing mutations were identified in 24 patients resulting in a molecular diagnosis rate of 14.8%. Coverage of the 24 CDG genes using panel testing and whole exome sequencing (WES) was compared and it was determined that many exons of these genes were not adequately covered using a WES approach and a panel approach may be the preferred first option for CDG patients. A collaborative effort between physicians, researchers and diagnostic laboratories will be very important as NGS testing using panels and exome becomes more widespread. This technology will ultimately improve the molecular diagnosis of patients with CDG in hard to solve cases. •CDG molecular testing includes single gene and next generation sequencing panels.•Molecular testing for CDG identified the likely gene defect in 14.8% of patients.•Whole exome sequencing has less adequate exon coverage compared to panels.•Variants will be reclassified as more population information becomes available.